Mark S Snyder's Insider Trades & SAST Disclosures
Mark S Snyder's most recent trade in Halozyme Therapeutics Inc. was a trade of 7,012 Common Stock done . Disclosure was reported to the exchange on Feb. 23, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mark S Snyder.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 7,012 | 32,264 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 7,012 | 21,033 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.75 per share. | 23 Feb 2025 | 3,775 | 28,489 (0%) | 0% | 57.7 | 218,006 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 22,603 | 22,603 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 21,327 | 21,327 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 17,409 | 0 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 17,409 | 32,411 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 16 Feb 2025 | 9,373 | 23,038 (0%) | 0% | 58.3 | 546,352 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 4,796 | 9,592 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 4,796 | 27,834 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 16 Feb 2025 | 2,582 | 25,252 (0%) | 0% | 58.3 | 150,505 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 30,050 | 30,050 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,269 | 7,269 | - | - | Performance Stock Unit | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,050 | 17,409 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 4,698 | 7,365 | - | - | Performance Stock Units | |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 32.50 per share. | 16 Jan 2025 | 10 | 3,996 (0%) | 0% | 32.5 | 325 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 7,611 | 19,291 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2025 | 7,611 | 7,611 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.74 per share. | 03 Jan 2025 | 4,289 | 15,002 (0%) | 0% | 47.7 | 204,757 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 36.11 per share. | 16 Oct 2024 | 9 | 3,958 (0%) | 0% | 36.1 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 36.11 per share. | 16 Jul 2024 | 9 | 3,926 (0%) | 0% | 36.1 | 325 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, CHIEF LEGAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 20,137 | 20,137 | - | - | Restricted Stock Units | |
| York Water Co. | Mark S Snyder | VP- Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2024 | 318 | 3,893 (0%) | 0% | 0 | Common Stock | |
| York Water Co. | Mark S Snyder | VP-Engineering | Purchase of securities on an exchange or from another person at price $ 36.56 per share. | 16 Apr 2024 | 9 | 3,575 (0%) | 0% | 36.6 | 329 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 29,064 | 29,064 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Snyder Mark | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 28,045 | 28,045 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 4,796 | 14,388 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 4,796 | 14,257 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Snyder Mark | SVP, GENERAL COUNSEL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.10 per share. | 16 Feb 2024 | 2,577 | 11,680 (0%) | 0% | 36.1 | 93,030 | Common Stock |
| York Water Co. | Mark Snyder S | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 40.62 per share. | 17 Jan 2024 | 8 | 3,544 (0%) | 0% | 40.6 | 325 | Common Stock |
| Halozyme Therapeutics Inc. | Snyder Mark | SVP, GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 7,611 | 12,418 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2024 | 7,611 | 15,222 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Snyder Mark | SVP, GENERAL COUNSEL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.78 per share. | 03 Jan 2024 | 2,957 | 9,461 (0%) | 0% | 35.8 | 105,801 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 40.62 per share. | 17 Jul 2023 | 8 | 3,486 (0%) | 0% | 40.6 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2023 | 249 | 3,460 (0%) | 0% | 0 | Common Stock | |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 46.43 per share. | 17 Apr 2023 | 7 | 3,211 (0%) | 0% | 46.4 | 325 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 54,955 | 54,955 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 19,184 | 19,184 | - | - | Restricted Stock Units | |
| York Water Co. | Mark S Snyder | VP-Engineering | Purchase of securities on an exchange or from another person at price $ 46.43 per share. | 18 Jan 2023 | 7 | 3,189 (0%) | 0% | 46.4 | 325 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 7,611 | 22,833 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 7,611 | 7,611 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, GENERAL COUNSEL | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.13 per share. | 03 Jan 2023 | 2,804 | 4,807 (0%) | 0% | 55.1 | 154,585 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 40.62 per share. | 17 Oct 2022 | 8 | 3,166 (0%) | 0% | 40.6 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 40.62 per share. | 18 Jul 2022 | 8 | 3,142 (0%) | 0% | 40.6 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 347 | 3,117 (0%) | 0% | 0 | Common Stock | |
| York Water Co. | Mark S Snyder | VP-Engineering | Purchase of securities on an exchange or from another person at price $ 41.23 per share. | 14 Apr 2022 | 13 | 2,762 (0%) | 0% | 41.2 | 536 | Common Stock |
| York Water Co. | Mark S Snyder | VP-Engineering | Purchase of securities on an exchange or from another person at price $ 46.43 per share. | 14 Apr 2022 | 7 | 2,770 (0%) | 0% | 46.4 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 48.36 per share. | 14 Jan 2022 | 11 | 2,742 (0%) | 0% | 48.4 | 532 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 54.17 per share. | 14 Jan 2022 | 6 | 2,749 (0%) | 0% | 54.2 | 325 | Common Stock |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 83,142 | 83,142 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Mark Snyder | SVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 30,444 | 30,444 | - | - | Restricted Stock Unit | |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 42.33 per share. | 15 Oct 2021 | 12 | 2,723 (0%) | 0% | 42.3 | 508 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 46.43 per share. | 15 Oct 2021 | 7 | 2,731 (0%) | 0% | 46.4 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 45.91 per share. | 15 Jul 2021 | 11 | 2,704 (0%) | 0% | 45.9 | 505 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 46.43 per share. | 15 Jul 2021 | 7 | 2,711 (0%) | 0% | 46.4 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2021 | 251 | 2,692 (0%) | 0% | 0 | Common Stock | |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 41.27 per share. | 15 Apr 2021 | 11 | 2,434 (0%) | 0% | 41.3 | 454 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 46.43 per share. | 15 Apr 2021 | 7 | 2,441 (0%) | 0% | 46.4 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 45.10 per share. | 15 Jan 2021 | 10 | 2,416 (0%) | 0% | 45.1 | 451 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 46.43 per share. | 15 Jan 2021 | 7 | 2,423 (0%) | 0% | 46.4 | 325 | Common Stock |
| York Water Co. | Mark S Snyder | VP-Engineering | Purchase of securities on an exchange or from another person at price $ 40.83 per share. | 15 Oct 2020 | 12 | 2,406 (0%) | 0% | 40.8 | 490 | Common Stock |
| York Water Co. | Mark S Snyder | VP-Engineering | Purchase of securities on an exchange or from another person at price $ 42.90 per share. | 15 Oct 2020 | 10 | 2,394 (0%) | 0% | 42.9 | 429 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2020 | 281 | 2,383 (0%) | 0% | 0 | Common Stock | |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 45.88 per share. | 15 Jul 2020 | 17 | 2,102 (0%) | 0% | 45.9 | 780 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 46.75 per share. | 15 Jul 2020 | 8 | 2,085 (0%) | 0% | 46.8 | 374 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 43.33 per share. | 15 Apr 2020 | 18 | 2,076 (0%) | 0% | 43.3 | 780 | Common Stock |
| York Water Co. | Mark S Snyder | VP- Engineering | Purchase of securities on an exchange or from another person at price $ 46.12 per share. | 15 Apr 2020 | 8 | 2,058 (0%) | 0% | 46.1 | 369 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges